Context Therapeutics Inc. financial data

Symbol
CNTX on Nasdaq
Location
2001 Market Street, Suite 3915 Unit #15, Philadelphia, PA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.34K % +16.4%
Debt-to-equity 4.53 % -14.3%
Return On Equity -30.9 % +47.4%
Return On Assets -29.6 % +47%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 91.9M shares +22.5%
Common Stock, Shares, Outstanding 91.9M shares +22.5%
Entity Public Float 148M USD +523%
Common Stock, Value, Issued 91.9K USD +22.5%
Weighted Average Number of Shares Outstanding, Basic 95.2M shares +18.3%
Weighted Average Number of Shares Outstanding, Diluted 95.2M shares +18.3%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 7.67M USD +8.67%
Operating Income (Loss) -30.2M USD +7.18%
Nonoperating Income (Expense) -66.3K USD -1979%
Net Income (Loss) Attributable to Parent -26.4M USD +12.3%
Earnings Per Share, Basic 0 USD/shares +76.9%
Earnings Per Share, Diluted 0 USD/shares +76.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 76.9M USD -9.27%
Assets, Current 79.1M USD -8.15%
Property, Plant and Equipment, Net 33.7K USD +126%
Operating Lease, Right-of-Use Asset 139K USD -43.2%
Other Assets, Noncurrent 0 USD -100%
Assets 79.2M USD -8.22%
Accounts Payable, Current 2.72M USD +165%
Employee-related Liabilities, Current 1.09M USD +74%
Accrued Liabilities, Current 3.2M USD +167%
Liabilities, Current 6.04M USD +159%
Operating Lease, Liability, Noncurrent 21.2K USD -84.9%
Liabilities 6.06M USD +145%
Retained Earnings (Accumulated Deficit) -118M USD -28.9%
Stockholders' Equity Attributable to Parent 73.2M USD -12.7%
Liabilities and Equity 79.2M USD -8.22%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.03M USD -15.3%
Net Cash Provided by (Used in) Financing Activities -15.3K USD
Net Cash Provided by (Used in) Investing Activities -33.9K USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 91.9M shares +22.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -5.08M USD -16.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 76.9M USD -9.27%
Deferred Tax Assets, Valuation Allowance 24.8M USD +49.1%
Deferred Tax Assets, Gross 25M USD +48.6%
Operating Lease, Liability 100K USD -50%
Payments to Acquire Property, Plant, and Equipment 33.9K USD
Operating Lease, Liability, Current 119K USD +14.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 9.32M USD +20.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 191M USD +8.98%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 4.06K USD +57.9%
Share-based Payment Arrangement, Expense 1.24M USD +42.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%